1,2,4-Triazolo[1,5a]Pyridine JAK2 Inhibitor Oral Bioavailability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for chronic systemic inflammatory disorders like rheumatoid arthritis, particularly those targeting JAK2 pathways, face challenges such as high production costs, requirement for multiple injections, and potential anaphylactic reactions with biologics, highlighting the need for safe and effective orally active small molecules that can inhibit key kinases involved in cytokine receptor signaling.

Innovation Solution

Development of a potent, orally active 1,2,4-Triazolo[1,5a]Pyridine derivative (Compound A) as a small molecule inhibitor of JAK2, which selectively inhibits JAK2 kinase activity, reducing inflammation by modulating cytokine pathways and administered in various dosage forms to treat chronic systemic inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If biologics are used to treat chronic systemic inflammatory disorders, then therapeutic effectiveness is improved, but production cost increases and administration complexity increases

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidadministration complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces the mechanical injection system required for biologics with an oral administration system. The small molecule inhibitor can be taken orally in tablet or capsule form, eliminating the need for injections, syringes, and complex injection schedules, thereby reducing administration complexity while maintaining therapeutic effectiveness through oral bioavailability

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the molecular size and chemical structure parameters from large protein-based biologics to small molecule inhibitors. This parameter change enables oral administration by improving oral bioavailability and reducing the molecular weight, thereby simplifying the administration system while preserving therapeutic activity against JAK2

Inventive Principle:

Principle #35Parameter changes

2Reliability

If biologics are used to treat chronic systemic inflammatory disorders, then therapeutic effectiveness is improved, but production cost increases

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidproduction cost

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent employs small molecule inhibitors that are significantly cheaper to manufacture compared to biologics. These small molecules can be produced using established chemical synthesis methods with lower production costs, avoiding the expensive fermentation, purification, and quality control processes required for protein-based biologics, thereby reducing production cost while maintaining therapeutic effectiveness

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent substitutes the complex biopharmaceutical manufacturing system for biologics with a simpler chemical synthesis system for small molecules. This substitution dramatically reduces production costs by eliminating the need for GMP-grade cell culture facilities, large-scale fermentation, and complex protein purification processes

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If biologics are used to treat chronic systemic inflammatory disorders, then therapeutic effectiveness is improved, but safety risks increase

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidsafety risks

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent replaces the biological product system with a small molecule inhibitor that has a different safety profile. The small molecule can be administered orally and has been shown to have favorable safety characteristics, avoiding the anaphylactic reactions and other serious adverse events associated with biologics, thereby reducing safety risks while maintaining therapeutic effectiveness

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent changes the molecular class from protein-based biologics to small organic molecules. This parameter change fundamentally alters the immunogenicity and safety profile, reducing the risk of anaphylactic reactions and other severe adverse effects while preserving the ability to inhibit JAK2 and treat chronic inflammatory disorders

Inventive Principle:

Principle #35Parameter changes

4Reliability

If multiple injections are required for treatment, then therapeutic coverage is improved, but patient convenience deteriorates

Engineering Contradiction:

Improvetherapeutic coverageVSAvoidpatient convenience

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent substitutes the injection-based delivery system with an oral delivery system. Patients can take the small molecule inhibitor orally in the convenience of their daily routine, eliminating the need for multiple injections, needle phobia, and complex injection scheduling, thereby dramatically improving patient convenience while maintaining continuous therapeutic coverage through daily oral dosing

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Data Source

PatentUS9034876B2Treatment of chronic inflammation with a 1,2,4-triazolo [1,5a] pyridine derivative

Publication Date: 2015.05.19 CEPHALON INC

AI summary

This application describes and provides a method of treating diseases or disorders characterized by chronic systemic inflammation, such as rheumatoid arthritis, using a compound that inhibits JAK2 kinase.